



**ASX Announcement**

**9 December 2021**

## **Board changes**

**SYDNEY Australia Thursday, 9 December 2021** – Atomo Diagnostics Limited (ASX: AT1) (**Atomo**) advises that Ms Connie Carnabuci has notified the Board of her resignation as a director of the Company with effect from 9 December 2021.

Ms Carnabuci was appointed to the Board as an independent Non-Executive Director on 4 February 2020 ahead of the Company's listing on the ASX and has been the Chair of Atomo's People, Culture and Remuneration Committee since that time.

Chair, John Keith, commented on the resignation: "Atomo has been very fortunate to have Connie during its formative stages as a publicly listed company. On behalf of the Board, I thank Connie for her valuable contribution to Atomo. Connie leaves our board with the very best wishes and thanks of her colleagues."

The Board has appointed Ms Deborah Neff to assume the role of chair of the People, Culture and Remuneration Committee effective 9 December 2021.

For more information, please contact:

Jane Lowe

IR Department

[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

Phone: +61 411 117 774

John Kelly

Atomo Diagnostics

[john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)

Phone: +61 401 922 279

*This announcement was authorised by the Board of Directors.*

### **About Atomo**

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com).